News
LRMR
7.94
+9.29%
0.68
Weekly Report: what happened at LRMR last week (0318-0322)?
Weekly Report · 3d ago
5 Stocks that Analysts Love in March 2024
TipRanks · 03/18 12:35
Weekly Report: what happened at LRMR last week (0311-0315)?
Weekly Report · 03/18 12:09
Buy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug Nomlabofusp
TipRanks · 03/15 20:15
Larimar Therapeutics Price Target Maintained With a $25.00/Share by JMP Securities
Dow Jones · 03/15 14:47
JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
Benzinga · 03/15 14:37
LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023
Larimar Therapeutics reported earnings per share of -30 cents. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -25 cents. Larimar Therapedutics was down 2.7% to $3.05 in the afternoon.
Investorplace · 03/15 01:53
Larimar Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Larimar Therapeutics Inc reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $12.99 million. Shares had risen by 104.4% this quarter. The average analyst rating on the shares is "strong buy"
Reuters · 03/14 21:46
*Larimar Therapeutics 4Q Loss/Shr 30c >LRMR
Dow Jones · 03/14 20:05
*Larimar Therapeutics 4Q Loss $13M >LRMR
Dow Jones · 03/14 20:05
Larimar Therapeutics Price Target Maintained With a $25.00/Share by JMP Securities
Dow Jones · 03/12 14:17
JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
Benzinga · 03/12 14:08
Buy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s Ataxia
TipRanks · 03/12 12:25
3 Best Stocks to Buy Now, 3/12/2024, According to Top Analysts
TipRanks · 03/12 10:09
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)
TipRanks · 03/12 04:40
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
Larimar Therapeutics, Inc. Announces dosing of the first patient in an open label extension study of nomlabofusp in participants with Friedreich's ataxia. Nomlabof Susp is a novel protein replacement therapy designed to address the root cause of the disease. The company is focused on developing treatments for complex rare diseases.
Barchart · 03/11 15:05
Weekly Report: what happened at LRMR last week (0304-0308)?
Weekly Report · 03/11 12:04
Top 10 best performing biotech stocks of 2024 so far
The biotech sector is +13.6% in 2024. Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors and computer peripherals industries. Top 10 best performing biotech stocks of 2024 so far are Elevation Oncology and Janux.
Seeking Alpha · 03/06 16:25
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Larimar Therapeutics, Inc. Is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Biopharma Conference in March 2024.
Barchart · 03/06 15:05
Weekly Report: what happened at LRMR last week (0226-0301)?
Weekly Report · 03/04 12:08
More
Webull provides a variety of real-time LRMR stock news. You can receive the latest news about Larimar Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.